Trial Profile
A Phase 1/2, Randomized, Observer-blind, Controlled, Multi-center, Dose-escalation Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A), When Administered Intramuscularly According to a 0, 1-month Schedule to RSV-seropositive Infants Aged 12 to 23 Months
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Dec 2022
Price :
$35
*
At a glance
- Drugs GSK 3389245A (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Acronyms RSV PED-002
- Sponsors GlaxoSmithKline; GSK
- 09 Dec 2022 Results published in the Journal of Infectious Diseases
- 23 Dec 2020 Status changed from active, no longer recruiting to completed.
- 22 Nov 2019 Planned End Date changed from 23 Nov 2020 to 18 Nov 2020.